CICS-UBI - Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal; Centre for Research and Technology of Agro-Environmental and Biological Sciences (CITAB), Inov4Agro, University of Trás-os-Montes and Alto Douro (UTAD), Quinta de Prados, 5000-801 Vila Real, Portugal.
Laboratoire d'Optique et Biosciences, École Polytechnique, CNRS, INSERM, Institut Polytechnique de Paris, 91120 Palaiseau, France.
Int J Biol Macromol. 2024 Jun;270(Pt 1):132244. doi: 10.1016/j.ijbiomac.2024.132244. Epub 2024 May 8.
To combat cancer, a comprehensive understanding of the molecular mechanisms and behaviors involved in carcinogenesis is crucial, as tumorigenesis is a complex process influenced by various genetic events and disease hallmarks. The B-MYB gene encodes a transcription factor involved in cell cycle regulation, survival, and differentiation in normal cells. B-MYB can be transformed into an oncogene through mutations, and abnormal expression of B-MYB has been identified in various cancers, including lung cancer, and is associated with poor prognosis. Targeting this oncogene is a promising approach for anti-cancer drug design. B-MYB has been deemed undruggable in previous reports, necessitating the search for novel therapeutic options. In this study, we found that the B-MYB gene promoter contains several G/C rich motifs compatible with G-quadruplex (G4) formation. We investigated and validated the existence of G4 structures in the promoter region of B-MYB, first in vitro using a combination of bioinformatics, biophysical, and biochemical methods, then in cell with the recently developed G4access method.
为了对抗癌症,全面了解致癌作用涉及的分子机制和行为至关重要,因为肿瘤发生是一个受多种遗传事件和疾病标志影响的复杂过程。B-MYB 基因编码一种参与正常细胞周期调控、存活和分化的转录因子。B-MYB 可以通过突变转化为癌基因,并且已经在包括肺癌在内的各种癌症中发现 B-MYB 的异常表达与预后不良有关。针对该癌基因是设计抗癌药物的一种有前途的方法。以前的报告认为 B-MYB 是不可成药的,因此需要寻找新的治疗选择。在这项研究中,我们发现 B-MYB 基因启动子包含几个与 G-四链体(G4)形成相容的 G/C 丰富基序。我们使用生物信息学、生物物理和生化方法的组合首先在体外研究和验证了 B-MYB 启动子区域中 G4 结构的存在,然后使用最近开发的 G4access 方法在细胞中进行了验证。